Immuron announced the issuance of a patent by the United States Patent and Trademark Office for a method to treat Clostridium difficile infections. The patent entitled “Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease” describes a targeted drug composition comprising an enriched, hyperimmune polyclonal antibody preparation of bovine colostrum for use in treating C. difficile, a bacterium that causes life threatening diarrhea. The company’s drug candidate IMM-529, which is based on this technology, is presently in a Phase 1/2a clinical trial in C. difficile patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.